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Abstract:

Background: Although the effectiveness of buprenorphine-naloxone (BUP-NX) has been
established, real-world evidence on the benefits of early treatment initiation is limited.

Objective: To evaluate the association between early BUP-NX initiation and health-related
outcomes among insured adults with opioid use disorder (OUD).

Methods: We conducted a cross-sectional analysis using the Optum’s de-identified
Clinformatics® Data Mart Database from 2010 to 2018. Patients who initiated BUP-NX within 30
days of OUD diagnosis were classified as early initiators. Patients who initiated BUP-NX later,
but within the one-year follow-up, were defined as late initiators. Outcomes included opioid
overdose, opioid overdose-related emergency department (ED) visits, and all-cause healthcare
cost during the year after OUD diagnosis. We employed generalized linear models to compare
outcomes between early and late initiators, adjusting for baseline covariates and accounting for
missing information for covariates using multiple imputation.

Results: A total of 8,388 patients with OUD were identified; mean age was 39.9 years; 36%
were female; and 67.6% were early initiators. Early initiators had an estimated 42% lower rate
of opioid overdose (adjusted rate ratio (aRR) = 0.58; 95% confidence interval (CI): 0.52, 0.64);
51% lower rate of opioid overdose-related ED visits (aRR = 0.49; 95% CI: 0.44, 0.55); and 31%
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lower total healthcare cost (adjusted cost ratio = 0.69; 95% CI: 0.66, 0.72), compared to late
initiators.

Conclusion: Compared to late BUP-NX initiation, early initiation was associated with a lower risk
of opioid overdose and opioid overdose-related ED visits, and reduced total healthcare cost
among insured adult patients with OUD.

Abstract word count = 249/250
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Introduction

The U.S. Department of Health and Human Services declared opioid use disorder (OUD) a
national public health crisis in 2015 (1, 2), attracting renewed scientific interest in identifying
implementation strategies to address the opioid epidemic. Several studies have shown that
OUD is associated with elevated morbidity, overdose-related mortality, and other adverse
health conditions (3-5). A systematic review and meta-analysis of 58 cohort studies of people
living with OUD found a pooled all-cause crude mortality rate of 20.9 per 1000 person-years
and a pooled standard mortality ratio of 14.7, with opioid overdose being the most common
cause of death (6). This crisis is exacerbated by the presence of the COVID-19 pandemic (7-9).
Based on the available data, drug overdose deaths started to increase from 2020 March and the
predicted count of 12 month drug overdose death was 95,230 by the first month of 2021 based
on avaible data on 2021 August 1st (10, 11).

There are more than an estimated 2 million people living with OUD in the US and the total cost
of the opioid crisis including, direct, indirect, and lost productivity, has been rising dramatically.
For example, the total cost of OUD care increased from 43.2 billion in 2009, 78.5 billion in 2013,
and $471 billion in 2017 (12-14). The increased cost of OUD and opioid-related overdose deaths
in the US has drawn more attention to the need to expand access to medications for opioid use
disorder (MOUD). The US Food and Drug Administration (FDA) has approved buprenorphine
(with/without naloxone), methadone, and injectable naltrexone for the treatment of OUD (15).
The American Society of Addiction Medicine’s updated national practice guidelines
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recommends the use of one of these three medications for OUD care (16). Although long-term
treatment of OUD has shown great promise in curbing the opioid overdose crisis, and patients
are initiated or maintained on long-term treatment after diagnosis. For example, from 2009 to
2013, only 1 in 5 patients living with OUD received any form of treatment (17). As a result,
access to MOUD continues to be limited for many people living with OUD due to provider,
pharmacy, geographic, regulatory, and financial barriers (18-21).

Of the three medications (buprenorphine, naltrexone, methadone) approved for OUD,
buprenorphine-naloxone (BUP-NX) is widely viewed as offering the greatest opportunity for
expanding access to medication treatment. Naltrexone initiation often requires detoxification
and an opioid-free period (22, 23), and higher induction failure rates have been observed
compared to buprenorphine (with or without naloxone) (24). Furthermore, a recent cohort
study showed that all-cause and opioid-related mortality rates during the first four-week after
treatment initiation were higher among patients treated with methadone as compared to those
who received buprenorphine (with or without naloxone): adjusted all-cause mortality RR: 2.17,
95% CI: 1.29, 3.76; adjusted opioid-related mortality RR: 7.61, 95% CI: 1.80, 31.94 (25). In
addition, maintaining methadone treatment requires frequent provider and counseling visits,
which places an additional burden on patients, particularly for patients who live in rural areas.
One study showed that people who lived in the rural census areas of Indiana, Kentucky, Ohio,
Virginia, and West Virginia had longer drive times than patients who lived in urban places of the
same five states (median drive time to methadone dispensing provider for rural versus urban:
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16.1 versus 48.4 minutes in 2018) (26). In the current OUD clinical management guidelines,
BUP-NX is the recommended treatment (27, 28).

Several studies have investigated the relationship between MOUD and all-cause mortality, but
very few have examined the association between timely initiation of treatment and healthrelated outcomes. A 2018 observational study found that timely initiation of MOUD (i.e., within
3-month after OUD diagnosis) was associated with a higher rate of retention on treatment
compared to the use of behavioral health services alone among youths (ages 13 -22) with OUD
(29). One randomized clinical trial compared immediate BUP-NX initiation in the emergency
department (ED) with brief behavioral intervention and/or referral without initiating MOUD
(30). Initiation of BUP-NX in the ED reduced self-reported illicit drug use and use of inpatient
services during a 30-day follow-up period, compared to patients who only received the brief
behavioral intervention and/or referral for treatment. In another small randomized trial, early
treatment with buprenorphine (initiated after randomization) resulted in significant reductions
in illegal opioid use compared to those who initiated treatment later at 4, 8, and 12 weeks,
respectively (31). These studies suggest that early initiation of BUP-NX may be a successful OUD
management strategy for many patients (16). However, the relationship between early BUP-NX
initiation and health-related outcomes (e.g., opioid overdose episodes, healthcare utilization,
and cost) has not yet been well studied. This study examined the association between early
BUP-NX initiation and health-related outcomes, including opioid overdose, opioid overdoserelated ED visits, and total healthcare cost, among insured adult patients living with OUD in the
United States from 2010 to 2018.
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Methods

We conducted a cross-sectional study using healthcare claims from the Optum’s de-identified
Clinformatics® Data Mart Database (OptumInsight, Eden Prairie, MN) (32). The data spanned
the period from January 1, 2010 through December 31, 2018. This study was approved by the
Institutional Review Board of the University of Rhode Island. The requirement for consent was
waived for deidentified claims data. To create the study sample, the following eligibility criteria
were applied to identify all adults with a diagnosis of OUD: 1) at least two separate outpatient
claims within 3 months of each other or one inpatient claim for OUD as the primary or
secondary diagnosis using the International Classification of Diseases, 9th and 10th Revision,
Clinical Modification (ICD-9/10-CM) code (Supplemental Table 1) (29, 33, 34); 2) at least one
year of continuous enrollment before the first eligible OUD diagnosis (index date); 3) at least
one year of continuous follow-up after the index date; 4) at least 18 years old as of the index
date; 5) initiate BUP-NX during the one-year following the index OUD diagnosis. The baseline
period was used to ascertain demographic and medical information. We defined the date of the
first observed OUD diagnosis in the database as the start of follow-up. Both the exposure and
the outcome were ascertained from the one-year follow-up period (Figure 1). The flowchart for
this study is shown in Figure 2.

Receipt of BUP-NX was identified using pharmacy claims by brand or generic names. Monoingredient buprenorphine was not considered as exposure. Because there was no information
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available for either the formulation or the indication, and we were not able to distinguish
whether the single ingredient buprenorphine was prescribed for pain or OUD management.
Early BUP-NX initiation was defined as receipt of BUP-NX within 30 days after the index date.
Patients who initiated BUP-NX after 30 days of the index OUD diagnosis during the follow-up
were classified as late initiators.

The study included four main outcomes: 1) the number of opioid overdose-related ED visits; 2)
any occurrence of opioid overdose; 3) counts of opioid overdose episodes, and 4) total
healthcare cost (including inpatient, outpatient, and prescription cost) during the one-year
period following OUD diagnosis. The occurrence of an opioid overdose was measured in terms
of the number of opioid overdoses episodes and as a binary indicator of whether a patient
experienced at least one opioid overdose during follow-up. Opioid overdose was identified
using ICD-9/10 codes in inpatient and outpatient claims. Opioid overdose claims separated by
at least 7 days were considered different overdose episodes (Supplemental Table 1). To identify
ED visits, we used the Yale ED identification algorithm, which utilizes the Healthcare Common
Procedure Coding System (HCPCS) codes, revenue codes, and place of service codes in the
database (35, 36). Total healthcare costs in the year following the index date were defined and
computed as the sum of the standard price of provider services for all inpatient and outpatient
medical claims and outpatient pharmacy files. The cost was adjusted for inflation to the 2018
US dollar using the Consumer Price Index inflation calculator from the Bureau of Labor Statistics
(37).
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Sociodemographic covariates included age at OUD diagnosis, gender, type of insurance
(commercial or Medicare Advantage), type of health plan, and self-reported socioeconomic
status (SES). Clinical baseline covariates included history of opioid overdose, history of opioid
utilization, opioid polypharmacy, Charlson comorbidity index (CCI), receipt of methadone
and/or naltrexone, daily morphine milligram equivalent (MME), history of chronic obstructive
pulmonary diseases, depression, receipt of antidepressants, history of alcohol use disorder, and
total healthcare cost during the baseline period (4). Opioid prescription information was
converted to daily MME using standard conversion factors provided by the Centers for Disease
Control and Prevention (CDC) (38). Paitents who had not received any prescription opioid
would have daily MME equal to zero. The CCI included 17 different conditions, such as
myocardial infarction and chronic obstructive pulmonary diseases, and it is widely used as a
measure of disease burden (39). Self-reported SES included race, house ownership, educational
level, household income level, household net worth, poverty level, and presence of a child in
the household. Some of the SES covariates were missing and only 58.4% of patients had
complete information (n = 4,899), and the missing pattern was not monotone (i.e., there was
not a natural ordering of variables, where for a given patient once one variable starts to have
missing value, all subsequent variables were also missing for that patient) (Supplemental Table
2). All baseline comorbidities were identified using ICD-9/10-CM from both inpatient and
outpatient records (Supplemental Table 1) (40).

Statistical Methods
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Baseline characteristics were summarized by the BUP-NX initiation group. Descriptive statistics
were calculated as mean with standard deviation (SD) for continuous variables and frequency
and proportion for categorical variables. We employed a generalized linear model (GLM) to
compare the outcomes between early BUP-NX initiation and late initiation groups. The log link
with a Poisson distribution was used for count outcomes with adjustment for overdispersion
(i.e., number of opioid overdose episodes and number of ED visits); the log link with a gamma
distribution for cost outcome (i.e., total healthcare cost); and the logit link with a binomial
distribution for the binary outcome (i.e., any occurrence of opioid overdose) (41).

We first fit an unadjusted model on the full study sample. Due to the missing data in selfreported SES, we conducted an adjusted comparison among complete cases adjusting for SES,
comorbidities, and concomitant medications. There was no evidence of collinearity among
baseline variables. To account for missing data in the SES variable, we employed multiple
imputation with a fully conditional specification (FCS), an imputation approach for continuous
and categorical variables. Twenty imputed datasets with complete information were generated
using multiple imputation by FCS. The exposure status, baseline information, and the outcome
were included in the imputation model. The coefficients estimated by GLM from twenty
imputed datasets were combined, and the confidence intervals were calculated using Rubin’s
estimator of the variance (42-44). Because the results from the imputation may depend on the
sequence in which variables are imputed (45), we conducted a sensitivity analysis with two
imputation sequences: 1) starting from variables that had the most missing value to the ones
that had the least; 2) starting from variables had the least missing value to the most. We also
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conducted a sensitivity analysis with different definitions of early initiation: initiation within 15
and initiation within 45 days. We also evaluated the impact of the calendar year (i.e., the
possible impact of policy changing across the study period) on our result by adding it as a
categorical variable into models. All statistical analyses were conducted using SAS, version 9.4
(SAS Institute, Cary, NC), and statistical tests were two-sided and conducted at the 0.05
significance level.

Results

Overall, 8,388 adult patients were diagnosed with OUD during the study period and were
prescribed BUP-NX sometime during the year following their diagnosis, 5,667 (67.6%) received
BUP-NX within 30 days of their OUD diagnosis (i.e., early BUP-NX initiators), while 2,721 (32.4%)
were late initiators (Table 1 and Figure 2, and Supplemental Table 3). Almost two-thirds of the
patients were male (64%), and the mean age was 39.9 years (SD = 14.74). More than two-thirds
of the patients were enrolled in commercial health insurance (77.5%), and the rest were
enrolled in Medicare Advantage (22.5%). Based on the available self-reported SES information,
most patients had a bachelor’s degree or less (85.6%), a majority were white (84.8%), and
about half had a household income of less than $75,000 (50.3%). Most patients were
homeowners (82.7%) and about two-thirds had a net worth of less than $250,000 (67.8%).
Furthermore, most patients were living above 400% federal poverty line (FPL) (74.8%), and
most living in a childless home (77.9%) (Supplemental Table 2). The average CCI at baseline was
0.03 (SD = 1.04), but half of the patients had a history of chronic pain (49.9%); less than onePage 12 of 31

third had depression (30.1%); 6.9% had chronic obstructive pulmonary disease; 6.0% had a
documented history of alcohol use disorder; and 2.9% had a history of opioid overdose. More
late initiators (32.6%) had received benzodiazepine dispensing prior to the OUD diagnosis than
early initiators (28.6%). Usage of benzodiazepine and/or alcohol could delay the initiation of
BUP-NX (46). The average total healthcare utilization cost during the baseline period was
$27,100 (SD = $59,380) (Table 1). Less than 5% of patients had received naltrexone or
methadone for OUD during the follow-up.

Overall descriptively in the study, 314 (3.7%) out of 8,388 patients in the study experienced at
least one opioid overdose during the one-year following their OUD diagnosis. Among the early
BUP-NX initiation group, 144 (2.5%) patients had in total 206 opioid overdose episodes (3.64
per 100 person-year). Table 2 shows, among the late BUP-NX initiation group, 170 patients
(6.3%) had a total of 220 opioid overdose episodes (8.09 per 100 person-year). The opioid
overdose-related inpatient visit rate among early initiators was 1 per 100 person-year and 2 per
100 person-year among late initiators. The average opioid overdose-related inpatient stay
length was 4.58 and 4.42 days per year for early and late initiators, respectively. For all-cause
healthcare utilization, the early initiators had 26.7 outpatient visits per year (SD = 23.60), 0.56
inpatient admissions per year (SD = 1.55), 10.91 days inpatient stay per year (SD = 17.20), and
2.07 ED visits per year (SD = 5.06). Among the late initiators, the average number of outpatient
visits per year was 35.59 (SD=29.98), the average number of inpatient admissions per year was
1.22 (SD = 1.92), the average days of inpatient stay per year was 14.34 (SD = 18.57), and the
average number of ED visits per year was 3.02 (SD = 6.41) (Table 2).
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Table 3 shows unadjusted average annual costs. The average annual cost of BUP-NX among
early initiators and the late initiators was $3,637 (SD = $2,987) and $2,320 (SD= $2,280),
respectively. The average opioid overdose-related spending during follow-up among early and
late initiators was $289 (SD = $3,557) and $605 (SD = $4643), respectively. For all-cause
spending, the average annual prescription medication cost was $7,125 (with 51% was due to
BUP-NX) for the early initiators and $5,803 (with 40% was due to BUP-NX) for the late initiators.
The average annual total healthcare utilization cost among the early and late initiators was
$34,316 (SD = $63,867) and $55,485 (SD = $84,874), respectively.

We compared the adjusted healthcare utilization between early BUP-NX initiators and late
initiators by the generalized linear model combined with multiple imputation. Compared to the
late initiators, the early BUP-NX initiators had a 42% reduction in the rate of opioid overdose
(adjusted relative risk (aRR) = 0.58, 95% confidence interval (CI): 0.52, 0.64); 51% reduction in
the rate of opioid overdose-related ED visit (aRR = 0.49, 95% CI: 0.44, 0.55); 48% reduction in
the odds of opioid overdose (adjusted odds ratio= 0.52, 95% CI: 0.41, 0.66); and 31% less total
healthcare cost (adjusted cost ratio (aCR) = 0.69, 95% CI: 0.66, 0.72) (Table 4). The results from
sensitivity analyses were comparable across different definitions of early treatment initiation
(Supplemental Table 4). The point estimate and the 95% confidence interval were comparable,
regardless of the imputation sequence (Supplemental Table 5). Furthermore, the results were
also consistent across different calendar years (Supplemental Table 6).

Page 14 of 31

Discussion

This cross-sectional study used a large national administrative claim dataset of more than 50
million insured patients in the United States from 2010 to 2018. The results provide evidence
that buprenorphine-naloxone (BUP-NX) treatment initiation for OUD within 30 days of the
initial OUD diagnosis is associated with clinical and cost benefits for the patient and the
healthcare system. Early BUP-NX initiation was associated with a lower risk of opioid overdose,
a lower rate of overdose-related ED visits, and reduced total healthcare cost during the year
following an initial OUD diagnosis, after adjusting for baseline sociodemographic and medical
characteristics.

Our findings are consistent with results from other previous studies. For example, Morgan et al.
(47) had shown that active buprenorphine (with or without naloxone) treatment versus
interrupted treatment was associated with a lower hazard of overdose among commercially
insured patients with OUD in the US (adjusted hazard ratio = 0.40; 95% CI: 0.35, 0.46).
Furthermore, Baser et al. (48) found that patients who received MOUD had lower total
healthcare utilization costs during the 6-month window after treatment initiation compared to
patients with OUD who did not initiate treatment. With the evidence supporting the benefit of
MOUD, a treatment cascade for diagnosis and treatment of OUD management was established by
Williams et al (49). However, access to medication treatment remains limited. In our study,

among the eligible adult patients with OUD (n= 55,608), only 15.1% (n = 8,388) received at least
one buprenorphine-naloxone dispensing during the year after the OUD diagnosis (Figure 2).
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These matches findings from other recent studies. After the Comprehensive Addiction and
Recovery Act passed by the U.S. Congress, there were only 10-20% of patients with OUD
received medications for OUD by estimation (19). During 2009-2013, 21.5% (95% CI: 19.1, 24.0)
patients with OUD had received any type of treatment for OUD (medication or nonpharmacological) during the previous 12 months (50).

Our study addresses a critical gap in knowledge for OUD treatment and some limitations
identified in prior studies. We successfully identified early initiators from claims data and
evaluated the association between timely BUP-NX initiation and opioid overdose, healthcare
utilization, and cost among insured adult patients with OUD. This study provides preliminary
evidence supporting timely BUP-NX treatment initiation. Our study also addressed the concern
about unmeasured confounding due to SES variables, a known risk factor for overdose, by
including available information in generalized linear models with multiple imputation. We
employed generalized linear models with multiple imputation to account for missing data,
leveraging important variables to control for possible imbalances between exposure groups.
We also conducted a series of sensitivity analyses to explore the impact of different exposure
definitions and the imputation approaches on the results.

We found that less opioid overdose-related cost was incurred among the early initiators
compared to the late initiators. However, BUP-NX treatment cost per patient was higher among
the early initiators. Overall, the unadjusted total healthcare utilization cost, including
prescription and in/outpatient cost regardless of disease, was much lower among the early
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BUP-NX initiators than late initiators, $34,316 and $55,485, respectively. Baser et al. (48) also
found that the cost of detoxification/rehabilitation and/or provider visits was 29% higher
among untreated patients compared to those who received MOUD. In another study,
immediate BUP-NX initiation in ED was more cost effective than a brief behavioral intervention
and referral among adult patients with OUD (51).

Our study has some limitations that are common in observational studies using administrative
claims data. Because the exposure was not randomly assigned, patient sociodemographic
information and medical history may not be balanced between the two groups. To address this
issue, we used the generalized linear models to adjust for possible confounders measured at
baseline, including gender, SES variables, and comorbidities. However, we did not have
information about the severity of OUD, illegal drug use, patient lifestyle, or community
distribution of naloxone and we could not ascertain whether the indexed OUD was the first one
during their lifetime. Although we used commonly employed codes from the literature, the
sensitivity and specificity of some of the diagnosis codes have not yet been validated. The
treatment initiation group and the outcomes were assessed during the same period. As a result,
the temporal sequence of exposure and outcomes was not guaranteed. Because of this type of
cross-sectional design, the results in this paper do not confer any causal interpretations, even
though patients were followed longitudinally. Lastly, we did not have information on mortality,
and the study population was restricted to patients with commercial insurance or Medicare
Advantage, which limits the generalizability of the findings.
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Conclusion

Initiation of buprenorphine-naloxone within 30 days of opioid use disorder diagnosis was
associated with a reduced occurrence of opioid overdose and a significant decrease in total
healthcare utilization and cost during the one-year period following the OUD diagnosis
compared to later initiation. These findings should be considered by clinicians when assessing
potential risks and clinical benefits of initiating BUP-NX among adults with OUD in routine
medical practice. Longitudinal cohort studies that ensure a temporal ordering between
exposure and outcomes, avoid conditioning on post-baseline variables, and use appropriate
methods to address confounding are warranted.
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Table 1 Descriptive summary of baseline medication and comorbidity information of the
analytical sample

Gender, n (%)1
Female
Male
Age (years) at OUD dx, Mean (SD)
Type of insurance, n (%)1
Commercial
Medicare Advantage
Type of health plan, n (%)1
Exclusive provider organization
Health maintenance organization
Point of service
Preferred provider organization
Indemnity or others2
Medical conditions, n (%)
Chronic pain
Depression
Alcohol use disorder
History of opioid overdose
Chronic pulmonary disease
CCI at baseline, Mean (SD)
90 days prior to OUD dx, n (%)
Benzodiazepine
Anti-depressants
180 days prior to OUD dx, n (%)
Multiple opioids Rx
Any opioid Rx
Mean daily MME 180 days prior to OUD
dx, Mean (SD) 3
Daily MME among patients received
prescription opioid 180 days prior to OUD
dx, Mean (SD)3
Medications during the follow-up, n (%)
Naltrexone
Methadone2
Baseline cost ($), Mean (SD)
Outpatient cost
Inpatient cost
Medication cost
ED visit cost
Total healthcare cost

Early initiators
(n = 5,667)

Late initiators
(n = 2,721)

Total
(n = 8,388)

2004 (35.4)
3663 (64.6)
40.78 (14.54)

1012 (37.2)
1709 (62.8)
38.07 (15.00)

3016 (36.0)
5372 (64.0)
39.90 (14.74)

4351 (76.8)
1316 (23.2)

2152 (79.1)
569 (20.9)

6503 (77.5)
1885 (22.5)

570 (10.1)
821 (14.5)
3312 (58.4)
263 (4.6)
701 (12.4)

239 (8.8)
429 (15.8)
1636 (60.1)
168 (6.2)
249 (9.2)

809 (9.6)
1250 (14.9)
4948 (59.0)
431 (5.1)
950 (11.3)

2807 (49.5)
1610 (28.4)
284 (5.0)
137 (2.4)
389 (6.9)
0.30 (1.06)

1381 (50.8)
914 (33.6)
216 (7.9)
107 (3.9)
189 (6.9)
0.30 (0.99)

4188 (49.9)
2524 (30.1)
500 (6.0)
244 (2.9)
578 (6.9)
0.30 (1.04)

1618 (28.6)
2119 (37.4)

886 (32.6)
1102 (40.5)

2504 (29.9)
3221 (38.4)

1398 (24.7)
2743 (48.4)
27.5 (52.7)

755 (27.7)
1436 (52.8)
34.0 (59.4)

2153 (25.7)
4179 (49.8)
29.6 (55.0)

56.8 (63.9)

64.4 (68.7)

59.4(65.7)

140 (2.5)
14 (0.2)

195 (7.2)
<11

335 (4.0)
<26

16086 (41823)
4283 (21339)
5490 (13452)
3976 (11113)
25859 (59473)

19963 (38887)
5366 (22457)
4354 (9371)
5231 (13593)
29683 (59115)

17344 (40931)
4634 (21713)
5121 (12289)
4383 (11981)
27100 (59380)

1 Values

of polytomous variables might not sum to 100% due to rounding
Categories were combined, or number was masked due to small cell count
3 Single-ingredient buprenorphine was included in the MME calculation
rx: prescription; dx: diagnosis; MME: morphine milligram equivalent
2
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Table 2 Descriptive summary of opioid overdose-related and all-cause healthcare utilization
Healthcare utilization during the one-year period
following opioid use disorder diagnosis

Early
initiators
(n = 5,667)

Late initiators
(n = 2,721)

Total
(n = 8,388)

Number of opioid overdose episodes, Mean (SD)
Number of patients who had at least one opioid
overdose, n (%)

0.04 (0.28)
144 (2.5)

0.08 (0.35)
170 (6.2)

0.05 (0.30)
314 (3.7)

Number of opioid overdose episodes among patients
who had at least one opioid overdose, Mean (SD)
Opioid overdose-related healthcare utilization, Mean
(SD)

1.43 (1.06)

1.29 (0.85)

1.36 (0.84)

Number of inpatient visits
Length of inpatient stay (day)*
Number of outpatient visits
Number of ED visits
All-cause healthcare utilization, Mean (SD)
Number of inpatient visits
Length of inpatient stay (day)*
Number of outpatient visits
Number of ED visits

0.01 (0.10)
4.58 (4.29)
0.06 (0.60)
0.03 (0.25)

0.02 (0.14)
4.42 (6.15)
0.11 (0.61)
0.08 (0.42)

0.01 (0.11)
4.51 (5.19)
0.07 (0.61)
0.04 (0.31)

0.56 (1.55)
10.91 (17.20)
26.74 (23.60)
2.07 (5.06)

1.22 (1.92)
14.34 (18.57)
35.59 (29.98)
3.02 (6.41)

0.77 (1.71)
12.52 (17.94)
29.61 (26.17)
2.38 (5.55)

ED: emergency department.
* The average length of inpatient stay was calculated among patients who had at least one inpatient admission.
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Table 3 Descriptive summary of opioid-related and all-cause healthcare cost per patient
Cost of different healthcare utilization
during one-year following opioid use
disorder diagnosis
Opioid overdose-related cost in US
dollars, Mean (SD)
ED visit cost
Inpatient visit cost
Outpatient visit cost
Total cost
Buprenorphine-naloxone cost, Mean
(SD)
All-cause healthcare cost in US dollars,
Mean (SD)
ED visit cost
Prescription cost
Inpatient visit cost
Outpatient visit cost
Total cost

Early initiators
(n = 5,667)

Late initiators
(n = 2,721)

Total
(n = 8,388)

54 (539)

194 (1308)

100 (869)

74 (1227)
215 (2585)
289 (3557)
3637 (2987)

138 (2045)
467 (2984)
605 (4643)
2320 (2281)

95 (1541)
297 (2723)
391 (3945)
3210 (2845)

3653 (10455)
7125 (11577)
6657 (28325)
20538 (42623)
34316 (63867)

5516 (12831)
5803 (9638)
14125 (34937)
35575 (57314)
55485 (84874)

4257 (11314)
6696 (11002)
9080 (30823)
25416 (48396)
41183 (72043)

ED: emergency department.
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Table 4 Comparison of outcomes between early buprenorphine-naloxone initiation group and
late initiation group during the one-year period following the OUD diagnosis
Outcomes

Unadjusted

Adjusted with
complete records

Adjusted with
MI

Count of opioid overdose episodes
(RR with 95% CI)
Count of opioid overdose-related ED
visit (RR with 95% CI)
Opioid overdose (OR with 95% CI)
Total healthcare cost (CR with 95%
CI)

0.45 (0.41, 0.49)

0.52 (0.46, 0.59)

0.58 (0.52, 0.64)

0.36 (0.32, 0.40)

0.43 (0.37, 0.49)

0.49 (0.44, 0.55)

0.39 (0.31, 0.49)
0.62 (0.59, 0.65)

0.44 (0.32, 0.61)
0.68 (0.64, 0.72)

0.52 (0.41, 0.66)
0.69 (0.66, 0.72)

RR: risk ratio; CI: Confidence Interval; OR: odds ratio; CR: cost ratio.
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Figure 1 Schematic of the cross-sectional study design
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Figure 2 Flowchart of cohort building based on in/exclusion criteria for a study of insured adult
patients with opioid use disorder in the United States, 2010 – 2018
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